Akeso Collaboration and License Agreement (Details) $ in Thousands, shares in Millions		1 Months Ended	2 Months Ended	3 Months Ended
	Mar. 06, 2023 USD ($)	Jan. 31, 2023 USD ($) shares	Mar. 06, 2023 USD ($)	Mar. 31, 2023 USD ($) patient	Mar. 31, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
In-process research and development				$ 520,915	$ 0
Issuance of common stock in lieu of cash for Akeso upfront payment				$ 45,900
Ivonescimab | China and Australia
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of patients dosed (over) | patient				750
Collaborative arrangement, transaction with party to collaborative arrangement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Collaborative arrangement, upfront payment			$ 500,000
Cash payment for collaborative arrangement, upfront payment			474,900
Collaborative arrangement, additional potential milestone payments		$ 4,500,000
Collaborative arrangement, potential regulatory milestone payments		1,050,000
Collaborative arrangement, potential commercial milestone payments		3,450,000
Collaborative arrangement, direct transaction costs			$ 115
Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment one
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash payment for collaborative arrangement, upfront payment		$ 274,900
Collaborative arrangement, common stock issued in lieu of cash upfront payment (in shares) | shares		10
Collaborative arrangement, upfront payment, paid in shares		$ 25,100
Issuance of common stock in lieu of cash for Akeso upfront payment		$ 45,900
Collaborative arrangement, transaction with party to collaborative arrangement, upfront payment two
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash payment for collaborative arrangement, upfront payment	$ 200,000